Kovaltry under the microscope: how does it perform in everyday care?

NCT ID NCT02941783

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and effective Kovaltry is for people with hemophilia A when used in routine medical practice. Researchers tracked 230 patients for side effects and bleeding episodes. The goal was to gather real-world information, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Kovaltry (a recombinant clotting factor VIII)

What this could lead to

If results confirm real-world safety and effectiveness, it may support continued use of Kovaltry for managing hemophilia A.

What could go wrong

This is an observational, post-marketing study with no control group. It cannot prove that Kovaltry works better than other treatments, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Many Locations

    Multiple Locations, Japan